CARSGEN-B

2171
10.0303.93% ( -0.410 )
Delay Closed: Nov 16, 16:08:11

Overview

CARSGEN-B (2171)

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T...

Open
10.360
High
11.050
Low
10.000
Prev. Close
10.440
Volume
2.82M
Turnover
28.99M
Avg Price
10.276
Bid/Ask Ratio
66.67%
Amplitude
10.06%
52wk High
28.600
Volume Ratio
0.76
Turnover Ratio
0.47%
52wk Low
10.000
HK Mkt Cap
5.96B
Market CapHKD
5.96B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.173
EPSDynamic
-0.258
EPSStatic
--
BVPS
2.13
P/B
4.70
HK Shares
594.25M
Dividend YieldTTM
--
DividendTTM
--
Shares
594.25M
Min lot size
500
Currency
HKD

CARSGEN-B Analyst Rating

View more

Forecast & Rating

Aug 25, 2026
Price forecast
HK$18.3883.28%
Forecast & RatingHold
3analysts
  • Strong buy33.33%
  • Buy33.33%
  • Hold0.00%
  • Sell33.33%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    CARsgen (2171.HK) reversed early gains to close at HK$10.00, down 4.21% from the prior HK$10.44, after spiking to HK$10.99 at the 09:30 open and then sliding to a HK$10.00 low at 14:47, finishing near the session bottom on a thin 0.47% turnover rate. The driver was the inclusion of satri-cel (zevorcabtagene autoleucel) in China's commercial health insurance innovative drug list, news that had already lifted the stock roughly 6% in a single session; the morning pop read as short-term profit taking, and pipeline items such as first-patient dosing for CT1190B in R/R LBCL did not extend the move. Q2 2026 revenue was HK$35.76m, up 28.08% year on year, while the net loss narrowed 6.73% to HK$38.50m and the net margin stayed at -107.66%. The shares are down 34.73% YTD, 65.03% below the HK$28.60 52-week high, and sit under both the MA20 of HK$11.045 and MA60 of HK$12.15, though volume did not show heavy distribution.

  2. Nov, 13

    CARsgen (2171.HK) gave up an early gain to close down 5.8% at HK$10.44, having opened at HK$11.04 and slid to an intraday low of HK$10.36 in the afternoon session on HK$20.05 million turnover and a thin 0.32% turnover rate. Pipeline news kept coming — an ASH 2026 abstract for CT1190B in lymphoma, plus first-patient dosing in China registrational trials for the allogeneic CAR-T candidates CT0596 and CT1190B — yet the shares sit only 1.85% above the HK$10.25 52-week low set in early November, 63.5% below the HK$28.6 peak of 19 April, beneath the MA20 of HK$11.13 and MA60 of HK$12.22, and down 31.85% year-to-date. Q2 2026 revenue rose 28.08% year on year to HK$35.76 million while the net loss narrowed 6.73% to HK$38.5 million, though a -107.66% net margin, -12.12% ROE and 4.9x PB still point to a company in its investment phase. While both allogeneic programmes remain early-stage, the pace of upcoming data readouts is the variable to watch.

  3. Nov, 9

    CARsgen-B (2171.HK) spiked and faded as 2026 ASH abstract acceptance drove the stock to HK$11.520 at 09:55, up 5.8% from the HK$10.890 previous close, before sliding to HK$11.150 in the afternoon and closing at HK$11.200, trimming the gain to 2.85% on 1.361 million shares worth HK$15.43 million. The trigger was news that CT1190B lymphoma and CT071 myeloma data will be presented at the 2026 ASH Annual Meeting. Fundamentals remain pre-profit: Q2 2026 revenue of HK$35.76 million grew 28.08% year on year, while the HK$38.50 million net loss narrowed 6.73%, leaving PB at 5.25. At HK$11.20 the shares sit just under the MA20 of 11.212 and well below the MA60 of 12.47, down 26.89% year to date, 60.84% below the April 19 peak of HK$28.6 and only 9.27% above the November 2 low of HK$10.25. The event-driven spike, though, lacks a follow-through catalyst absent further clinical readouts.

  4. Nov, 4

    CARsgen-B opened lower but climbed to a session-high close of HK$11.02, up 5.35%, after ESMO 2026 poster data on Kailimei® as consolidation therapy for postoperative gastric cancer, alongside the first patient dosed in the China Phase I registrational trial of CT0596. The shares touched HK$10.35 at 10:02 BJ before reaching HK$11.02 at 14:38, on 1.95 million shares and HK$20.8 million turnover. Q2 2026 revenue rose 28.08% year on year to HK$35.8 million, net loss narrowed 6.73% to HK$38.5 million, while operating loss stayed at HK$77.1 million; PE is -63.78 and PB 5.17. The price sits 7.51% above the 52-week low of HK$10.25 set on 2 November, yet is still down 28.07% year to date, 61.47% below the 19 April high of HK$28.60 and under the MA20 of HK$11.34. Though the listing-rule compliance gap left by the non-executive director's resignation remains unfilled.

  5. Oct, 22

    CARsgen-B opened at HK$12.000 on Oct 22 and drifted lower through the day, closing the afternoon session at HK$10.800 and pinned to its 52-week low on 1.9625 million shares worth about HK$21.9 million. The slide came even as CT0596 and CT1190B, two allogeneic CAR-T candidates, each dosed a first patient in China Phase I registrational trials, and Q2 revenue reached HK$35.76 million, up 28.1% year on year, with a net loss of HK$38.5 million and EPS of -HK$0.0698, a 6.7% narrowing. A non-executive director resignation left the company non-compliant with one listing rule, compounding an earlier -5.68% low-volume weekly fade. The shares trade below the MA20 of HK$12.109 and MA60 of HK$13.131, down 29.5% year to date and 62.2% under the April 19 52-week high of HK$28.600, with PB at 5.07 and negative PE. Though turnover of just 0.33% leaves the signal thin.

News

Bullish vs. Bearish — Last 3 Months

6.8k followers · 0 opinions
▲Bullish50%
50%Bearish▼